BeiGene Ltd.
- Country
- 🇨🇳China
- Ownership
- Public
- Established
- 2010-01-01
- Employees
- 10K
- Market Cap
- $22.1B
- Website
- http://www.beigene.com
Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Conditions
- Non-Small Cell Lung Cancer (NSCLC)
- Interventions
- First Posted Date
- 2021-06-10
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 377
- Registration Number
- NCT04921358
- Locations
- 🇨🇳
Xinqiao Hospital Affiliated to the Army Medical University, Chongqing, Chongqing, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
🇦🇺The Northern Hospital, Epping, Victoria, Australia
Study of BGB-11417 in Adult Participants With Mature B-cell Malignancies
- First Posted Date
- 2021-05-12
- Last Posted Date
- 2024-11-29
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 64
- Registration Number
- NCT04883957
- Locations
- 🇨🇳
Peking University Peoples Hospital, Beijing, Beijing, China
🇨🇳Sun Yat Sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳The First Affiliated Hospital of Nanchang University Branch Donghu, Nanchang, Jiangxi, China
A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung Cancer
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2021-04-29
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 63
- Registration Number
- NCT04866017
- Locations
- 🇺🇸
XCancer/Centeral Care Center, Bolivar, Missouri, United States
🇦🇺Southern Medical Day Care Centre, Wollongong, New South Wales, Australia
🇦🇺Townsville Hospital, Douglas, Queensland, Australia
A Study of BGB-11417 in Participants With Myeloid Malignancies
- Conditions
- Acute Myeloid LeukemiaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Neoplasm
- Interventions
- First Posted Date
- 2021-02-25
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 260
- Registration Number
- NCT04771130
- Locations
- 🇫🇷
Hopital Saint Louis, Paris, France
🇩🇪Universitaetsklinikum Leipzig Aor, Leipzig, Germany
🇩🇪Universitaetsklinikum Ulm, Ulm, Germany
A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer
- Conditions
- Non-small Cell Lung CancerNSCLC
- Interventions
- First Posted Date
- 2021-02-10
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 662
- Registration Number
- NCT04746924
- Locations
- 🇦🇷
Centro Medical Austral, Buenos Aires, Argentina
🇦🇺Concord Repatriation General Hospital, Concord, New South Wales, Australia
🇦🇺Northern Cancer Institute, St Leonards, New South Wales, Australia
Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
- Conditions
- Esophageal Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2021-02-01
- Last Posted Date
- 2025-01-31
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 125
- Registration Number
- NCT04732494
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
🇨🇳Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan
🇹🇭Phramongkutklao Hospital, Bangkok, Thailand
Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid Tumors
- First Posted Date
- 2021-01-20
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 84
- Registration Number
- NCT04716634
- Locations
- 🇨🇳
Fujian Cancer Hospital, Fuzhou, Fujian, China
🇨🇳Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
🇨🇳Liaocheng Peoples Hospital, Liaocheng, Shandong, China
AdvanTIG-202: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Previously Treated Recurrent or Metastatic Cervical Cancer
- Conditions
- Cervical Cancer
- Interventions
- First Posted Date
- 2021-01-05
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 178
- Registration Number
- NCT04693234
- Locations
- 🇧🇬
"Mhat uni hospital" ood, Panagyurishte, Bulgaria
🇧🇬Complex Oncology Center Rousse Eood, Ruse, Bulgaria
🇧🇬Medical center nadezhda clinical eood, Sofia, Bulgaria
BGB-DXP604 Alone and in Combination With BGB-DXP593 in Healthy Participants
- First Posted Date
- 2020-12-16
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 25
- Registration Number
- NCT04669262
- Locations
- 🇦🇺
Q PHARM, Herston, Queensland, Australia
BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors
- Conditions
- Advanced Solid Tumor
- Interventions
- First Posted Date
- 2020-12-02
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 157
- Registration Number
- NCT04649385
- Locations
- 🇰🇷
The Catholic University of Korea, Seoul St Marys Hospital, SeochoGu, Seoul Teugbyeolsi, Korea, Republic of
🇺🇸Icahn School of Medicine At Mount Sinai, New York, New York, United States
🇺🇸The University of Texas Md Anderson Cancer Center, Houston, Texas, United States